Valuation: NuCana plc

Market Cap 4.17M 3.63M 3.43M 3.12M 5.83M 399M 5.86M 40.9M 15.82M 203M 15.65M 15.3M 649M P/E 2024
-0.15x
P/E 2025 -0.2x
Enterprise Value -19.41M -16.91M -16M -14.54M -27.16M -1.86B -27.29M -191M -73.69M -945M -72.91M -71.29M -3.02B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
99%
Yield 2024 *
-
Yield 2025 -
1 day+2.31%
1 week-0.75%
Current month-9.52%
1 month-14.19%
3 months-28.49%
6 months-28.49%
Current year-63.06%
1 week 1.3
Extreme 1.3
1.37
1 month 1.3
Extreme 1.3
1.9
Current year 1.21
Extreme 1.21
3.81
1 year 1.21
Extreme 1.21
7.22
3 years 1.21
Extreme 1.21
4,051
5 years 1.21
Extreme 1.21
16,598.5
10 years 1.21
Extreme 1.21
160,000
Manager TitleAgeSince
Chief Executive Officer 58 2008-03-19
Director of Finance/CFO - 2018-12-31
Chief Tech/Sci/R&D Officer - 2021-12-31
Director TitleAgeSince
Director/Board Member 58 2008-03-19
Director/Board Member 68 2009-12-13
Director/Board Member 72 2018-04-30
Date Insider Type Main position Quantity % Market Cap. Importance
4/15/26 Free

Chief Operating Officer

132,600,130 -
3/18/26 Other

Head of Translational Medicine

283,984,182 -
3/18/26 Other

Founder

4,352,841,381 -
Change 5-day change 1-year change 3-year change Capi.($)
+2.31%-0.75%-66.37%-99.96% 5.6M
+1.76%+3.62%+49.92%+101.12% 69.69B
+2.29%+0.32%+37.65%+77.03% 61.24B
+1.14%-2.59%-14.37%+366.97% 26.77B
+0.32%+2.58%+29.26%+14.12% 26.12B
+2.95%+2.34%+0.52%-9.52% 24.07B
+1.49%+5.15%+26.46%-15.89% 20.39B
-0.83%-11.15%+169.70%+295.44% 15.72B
+3.01%+1.85%+44.63%+173.96% 14.07B
+0.17%-4.07%-9.71%+484.05% 14.03B
Average +1.46%-1.58%+26.77%+138.73% 27.21B
Weighted average by Cap. +1.60%+0.20%+36.29%+129.68%

Financials

2024 2025
Net sales - -
Net income -19M -16.55M -15.66M -14.23M -26.58M -1.82B -26.71M -187M -72.12M -925M -71.36M -69.78M -2.96B -29.35M -25.57M -24.2M -21.98M -41.07M -2.81B -41.27M -288M -111M -1.43B -110M -108M -4.57B
Net Debt -6.56M -5.71M -5.41M -4.91M -9.18M -628M -9.22M -64.4M -24.9M -319M -24.64M -24.09M -1.02B -23.58M -20.53M -19.43M -17.66M -32.99M -2.26B -33.15M -231M -89.5M -1.15B -88.56M -86.59M -3.67B
Logo NuCana plc
NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-7738 and NUC-3373. NUC-7738 is an anti-cancer agent that disrupts Ribonucleic acid (RNA) polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase II part of a Phase I/II study which is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. NUC-3373 is a chemical entity derived from the nucleoside analog 5-fluorouracil, a chemotherapy agent. NUC-3373 is being evaluated in a Phase Ib/II modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer.
Employees
11
Date Price Change Volume
26-09-17 US$1.330 +2.31% 47,140
26-09-16 US$1.300 0.00% 19,203
26-09-15 US$1.300 -1.52% 65,812
26-09-14 US$1.320 0.00% 13,689
26-09-11 US$1.320 -1.49% 25,116

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NCNA Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!